MIT's in-body immune cell hack could revolutionize cancer and autoimmune treatment

MIT researchers have developed a technique that reprograms natural killer (NK) immune cells directly inside the body using lipid nanoparticles (LNPs) loaded with mRNA — no lab extraction required. The nanoparticles deliver genetic instructions that teach NK cells to produce chimeric antigen receptors (CARs), turning them into precision cancer fighters. Unlike current CAR T cell therapies, which require collecting, modifying, and re-infusing a patient's own cells over weeks, this approach could one day be as simple as a single infusion.

The technology is particularly promising for cancers and autoimmune diseases driven by abnormal T cells — a space where traditional CAR T therapies struggle, since engineered T cells can accidentally destroy each other. NK cells sidestep that problem entirely. In mouse studies, nanoparticle-treated animals saw tumors completely eliminated in T cell lymphoma models, and a single injection reversed liver damage in autoimmune hepatitis.

By the Numbers:

• ~80% of targeted NK cells were successfully reprogrammed after nanoparticle injection
• 3 out of 5 melanoma-model mice achieved complete remission
• T cell lymphoma tumors were fully eliminated after 5 nanoparticle injections
• 1 injection was enough to reverse autoimmune liver damage in mice

Why it matters: Current CAR T cell therapies are effective but notoriously expensive and logistically complex. A nanoparticle-based, in-body approach could dramatically lower costs and expand access — potentially bringing cutting-edge immunotherapy to far more patients, and opening new doors for treating autoimmune diseases like multiple sclerosis and rheumatoid arthritis.